216 related articles for article (PubMed ID: 19838023)
1. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
[TBL] [Abstract][Full Text] [Related]
2. [Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
Sumii T; Funakoshi A; Mizumoto K; Tanaka M; Arita Y; Ito T; Yamaguchi H; Ueki T; Sakai T; Miyahara T; Muranaka T; Igarashi H; Shinozaki H; Eriguchi N
Gan To Kagaku Ryoho; 2008 Apr; 35(4):603-6. PubMed ID: 18408428
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
Niki T; Yamamoto Y; Tsuda M; Horita K; Hirohata S; Nishisaki H
Gan To Kagaku Ryoho; 2009 Feb; 36(2):273-8. PubMed ID: 19223744
[TBL] [Abstract][Full Text] [Related]
5. [A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Hatata T; Takaya S; Taniguchi K; Naka T; Kondo A; Ikeguchi M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):109-12. PubMed ID: 21368469
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Nakamori S; Endo W; Ozato H; Shibata T; Takeda Y; Tohno K; Hasuike Y; Masutani S; Morimoto T; Doki Y; Mori M; Monden M
Gan To Kagaku Ryoho; 2011 May; 38(5):789-92. PubMed ID: 21566438
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Hara T; Nagata M; Yamashita Y; Fujimoto K; Muraki Y; Yasuda Y; Kurahashi T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1233-7. PubMed ID: 18633271
[TBL] [Abstract][Full Text] [Related]
8. [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Nakamori S; Tujie M; Takahashi Y; Maruhashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Gan To Kagaku Ryoho; 2004 Jan; 31(1):51-4. PubMed ID: 14750321
[TBL] [Abstract][Full Text] [Related]
9. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T
Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
11. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Nio Y; Hashimoto K; Yano S; Itakura M; Koike M; Yamaguchi K; Endo S; Tsuji M; Higami T; Maruyama R
Oncol Rep; 2005 Aug; 14(2):401-8. PubMed ID: 16012722
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M;
Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Xu Y; Guo X; Fan Y; Wang D; Wu W; Wu L; Liu T; Xu B; Feng Y; Wang Y; Lou W; Zhou Y
Jpn J Clin Oncol; 2018 Jun; 48(6):535-541. PubMed ID: 29718363
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Kanai M; Yoshimura K; Asada M; Imaizumi A; Suzuki C; Matsumoto S; Nishimura T; Mori Y; Masui T; Kawaguchi Y; Yanagihara K; Yazumi S; Chiba T; Guha S; Aggarwal BB
Cancer Chemother Pharmacol; 2011 Jul; 68(1):157-64. PubMed ID: 20859741
[TBL] [Abstract][Full Text] [Related]
17. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
Tanno S; Nakano Y; Osanai M; Koizumi K; Izawa T; Habiro A; Mizukami Y; Yanagawa N; Fujii T; Okumura T; Kohgo Y
Chemotherapy; 2006; 52(2):98-102. PubMed ID: 16567941
[TBL] [Abstract][Full Text] [Related]
19. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Miyagawa K; Yata Y; Yamaoka N; Sagara Y
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125
[TBL] [Abstract][Full Text] [Related]
20. [A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
Sugimoto K; Okada K; Nakahira S; Okamura S; Miki H; Nakata K; Suzuki R; Yoshimura M; Uji K; Yoshida A; Tamura S
Gan To Kagaku Ryoho; 2009 Feb; 36(2):321-3. PubMed ID: 19223756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
